197 related articles for article (PubMed ID: 31435905)
1. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
3. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
4. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
5. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
Brussee JM; Sidharta PN; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
Sidharta PN; Lindegger N; Ulč I; Dingemanse J
J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
[TBL] [Abstract][Full Text] [Related]
8. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
Sidharta PN; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
[TBL] [Abstract][Full Text] [Related]
9. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
Sidharta PN; Fischer H; Dingemanse J
Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
[TBL] [Abstract][Full Text] [Related]
10. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment.
Berger B; Muehlan C; Klein G; Dingemanse J
Clin Transl Sci; 2021 Nov; 14(6):2132-2138. PubMed ID: 34121345
[TBL] [Abstract][Full Text] [Related]
12. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
[TBL] [Abstract][Full Text] [Related]
13. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
[TBL] [Abstract][Full Text] [Related]
14. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
16. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
18. Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
Cho YS; Noh YH; Lim HS; Cho SH; Ghim JL; Choe S; Kim SB; Park JS; Lee SK; Yang WS; Chang JW; Bahng MY; Bae KS
J Clin Pharmacol; 2018 Jul; 58(7):905-912. PubMed ID: 29537612
[TBL] [Abstract][Full Text] [Related]
19. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
Angeli F; Verdecchia P; Reboldi G
Cardiol Ther; 2021 Dec; 10(2):397-406. PubMed ID: 34251649
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
